Benavides, FelipeGrossman, NicolePoggi, HelenaNieto, ElenaBertrán, AntonioAraos, DanielVásquez, MarcosIbarra, IgnazCaceres, FelipeEspinoza, KarenaLagos, MarcelaRepetto, Gabriela2017-05-032017-05-032015Benavides, Felipe, Grossman, Nicole, Poggi, Helena, Nieto, Elena, Bertrán, Antonio, Araos, Daniel, Vásquez, Marcos, Ibarra, Ignaz, Cáceres, Felipe, Espinoza, Karena, Lagos, Marcela, & Repetto M, Gabriela. (2015). Efecto de las variantes de VKORC1 y CYP2C9 sobre la dosis de anticoagulantes orales en individuos chilenos. Revista médica de Chile, 143(11), 1369-1376.http://hdl.handle.net/11447/1183http://dx.doi.org/10.4067/S0034-98872015001100001Centro de Genética y GenómicaBACKGROUND: The dose of oral anticoagulants (OAC) shows great variability among patients. Pharmacogenetic studies have shown that common variants in genes CYP2C9 (*2 and *3) and VKORC1 (-1639G>A) are associated with lower requirements of OAC. AIM: To study the association between average maintenance doses of oral anticoagulant therapy required to maintain a stable INR and CYP2C9 and VKORC1 gene variants in Chilean adults. MATERIAL AND METHODS: Prospective study of patients on anticoagulant treatment and with a stable international normalized ratio (INR) for prothrombin time for at least three months. Patients were classified as having high or low acenocoumarol or warfarin requirements. Peripheral blood DNA genotyping was performed by polymerase chain reaction and restriction fragment polymorphism or sequencing and electrophoresis. RESULTS: The study included 185 patients, 125 on acenocoumarol and 60 on warfarin. Patients with VKORC1-1639A allele were more likely to require lower doses of both drugs than patients with the G allele (Odds ratio [OR] for acenocoumarol 9.06, and OR for warfarin = 18.7). There was no association between CYP2C9*2 and*3 and acenocoumarol or warfarin requirements. CONCLUSIONS: There is an association between VKORC1-1639A variant and anticoagulant doses.8spaAcenocoumarolCytochrome P-450 CYP2CPharmacogeneticsVKORC1, protein, humanWarfarinArtículo